GO:0047105 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0047105 defines the NAD+-dependent oxidation of 4-(trimethylamino)butanal (4-aminobutyraldehyde) to 4-(trimethylamino)butanoate (GABA), a reaction first characterized in rat brain.
• The enzyme belongs to the aldehyde dehydrogenase superfamily, which typically uses NAD+ as a cofactor and can exhibit esterase side activities.
• This activity is part of the GABA shunt and polyamine catabolism, linking it to neurotransmitter homeostasis and cellular stress responses.
• NAD+ availability and the NAD+/NADH ratio directly influence catalytic efficiency, as shown for related dehydrogenases.
• Kinetic and inhibition studies of aldehyde dehydrogenases provide a framework for understanding substrate specificity and regulation of this activity.
• CRISPR-based knockout, point-mutation, and knock-in models enable precise interrogation of this enzyme's role in metabolic and neurological pathways.
Description
4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity (GO:0047105) catalyzes the oxidation of 4-(trimethylamino)butanal to 4-(trimethylamino)butanoate (GABA) using NAD+ as an electron acceptor. This reaction is a key step in the metabolism of polyamines and in the GABA shunt, a pathway that bypasses two steps of the TCA cycle to produce succinate. The enzyme was initially described in rat brain as 4-aminobutyraldehyde dehydrogenase, highlighting its role in neurotransmitter-related metabolism. Because aldehyde dehydrogenases are a large superfamily with diverse substrate specificities, understanding the unique features of this activity is essential for researchers studying metabolic and neurological disorders. The reaction is NAD+-dependent, and its kinetics are influenced by cofactor availability and the redox state of the cell, as demonstrated for related dehydrogenases. This article synthesizes authoritative QuickGO annotation data with verified PubMed literature to provide a research-grade overview of GO:0047105, its mechanism, associated genes, and experimental approaches.
4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity At A Glance
| GO ID | GO:0047105 |
|---|---|
| GO term | 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity |
| Ontology | molecular_function |
| Synonym | 4-N-trimethylaminobutyraldehyde dehydrogenase activity; 4-trimethylaminobutyraldehyde dehydrogenase activity; 4-trimethylammoniobutanal:NAD+ 1-oxidoreductase activity |
| Definition | Catalysis of the reaction: 4-(trimethylamino)butanal + NAD+ + H2O = 4-(trimethylamino)butanoate + NADH + 2 H+. |
| Major function | NAD+-dependent oxidation of 4-(trimethylamino)butanal to 4-(trimethylamino)butanoate (GABA) |
| Cofactor | NAD+ (nicotinamide adenine dinucleotide) |
| Substrate | 4-(trimethylamino)butanal (also known as 4-aminobutyraldehyde) |
| Product | 4-(trimethylamino)butanoate (GABA) and NADH |
| Pathway context | GABA shunt and polyamine catabolism |
| EC number | 1.2.1.- (aldehyde dehydrogenase family) |
What Is GO:0047105?
GO:0047105 describes the catalysis of the reaction: 4-(trimethylamino)butanal + NAD+ + H2O = 4-(trimethylamino)butanoate + NADH + 2 H+. In simpler terms, it is an NAD+-dependent aldehyde dehydrogenase activity that converts a trimethylammonium-containing aldehyde into its corresponding carboxylic acid, producing NADH and protons. The term is classified under molecular_function and is synonymous with 4-N-trimethylaminobutyraldehyde dehydrogenase activity, 4-trimethylaminobutyraldehyde dehydrogenase activity, and 4-trimethylammoniobutanal:NAD+ 1-oxidoreductase activity.
Why Is 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity Important in Cell Biology?
GO:0047105 is important because it links polyamine metabolism to GABA production, a neurotransmitter critical for inhibitory signaling in the central nervous system. Dysregulation of aldehyde dehydrogenases has been implicated in neurological and metabolic disorders, and the NAD+-dependence ties this activity to cellular redox balance and energy metabolism. Understanding this enzyme's kinetics and regulation can inform studies on neuroprotection, metabolic engineering, and drug development targeting aldehyde dehydrogenases.
• Contributes to GABA synthesis via the GABA shunt, influencing neuronal inhibition.
• Connects polyamine catabolism to neurotransmitter production.
• NAD+-dependent activity links it to cellular redox homeostasis and energy metabolism.
• Aldehyde dehydrogenase superfamily members are drug targets for various diseases.
• Kinetic properties can be altered by NAD+ availability, as shown for related dehydrogenases.
• Provides a model for studying substrate specificity within the aldehyde dehydrogenase family.
• Relevant to metabolic engineering for GABA production in microbial systems.
• Potential biomarker for disorders involving aldehyde accumulation.
Molecular Mechanism of 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity
Substrate Binding and Cofactor Interaction
In simple terms: The enzyme first grabs its substrate and the NAD+ helper molecule.
The enzyme binds 4-(trimethylamino)butanal and NAD+ in a sequential or ordered manner, forming a ternary complex. The aldehyde group of the substrate is positioned near the catalytic cysteine residue, while NAD+ is oriented to accept hydride. This step is critical for specificity, as aldehyde dehydrogenases discriminate among various aldehydes. The NAD+ binding affinity can be modulated by the cellular redox state, as observed for other dehydrogenases.
Hydride Transfer and Thiohemiacetal Formation
In simple terms: A hydride ion is moved from the substrate to NAD+, creating NADH.
The catalytic cysteine attacks the aldehyde carbon, forming a thiohemiacetal intermediate. Hydride transfer from the substrate to NAD+ yields NADH and a thioester intermediate. This mechanism is conserved among aldehyde dehydrogenases, as demonstrated for human liver aldehyde dehydrogenase. The rate of hydride transfer can be influenced by NAD+ concentration and the presence of inhibitors.
Hydrolysis and Product Release
In simple terms: Water breaks the intermediate, releasing the final acid product.
Hydrolysis of the thioester intermediate by water produces 4-(trimethylamino)butanoate (GABA) and regenerates the free enzyme. NADH is released, completing the catalytic cycle. The overall reaction also releases two protons, contributing to local pH changes. This step is analogous to other NAD+-dependent aldehyde dehydrogenases.
Cofactor Regeneration and Redox Balance
In simple terms: NADH must be recycled back to NAD+ for the enzyme to keep working.
The NADH produced must be reoxidized to NAD+ by the respiratory chain or other pathways to sustain catalysis. The NAD+/NADH ratio thus directly affects enzyme activity, as shown for lactate dehydrogenase and other dehydrogenases. In cells with high glycolytic flux, NAD+ regeneration is tightly linked to mitochondrial respiration.
Regulation by Substrate Availability and Inhibitors
In simple terms: The enzyme's speed depends on how much substrate is around and whether inhibitors are present.
Substrate availability, particularly 4-(trimethylamino)butanal derived from polyamine oxidation, controls flux through this reaction. Inhibitors such as polymeric NAD derivatives can reduce activity, as demonstrated for lactate dehydrogenase. Additionally, aldehyde dehydrogenase inhibitors like disulfiram may affect this activity, though specific data for GO:0047105 are limited.
Key Genes Involved in GO:0047105 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity
The following genes encode enzymes or related proteins that exhibit or are associated with 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity, based on published biochemical and genetic studies.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ALDH9A1 | Encodes a human aldehyde dehydrogenase that can oxidize 4-aminobutyraldehyde | Candidate gene for GABA-related disorders; target for kinetic studies |
| ALDH1A1 | Human liver aldehyde dehydrogenase with broad substrate specificity | Model for understanding aldehyde dehydrogenase esterase activity |
| ALDH2 | Mitochondrial aldehyde dehydrogenase involved in acetaldehyde metabolism | Relevant to NAD+-dependent aldehyde oxidation mechanisms |
| ALDH3A1 | Cytosolic aldehyde dehydrogenase with diverse substrates | Potential homolog for comparative studies |
| ALDH5A1 | Succinic semialdehyde dehydrogenase, involved in GABA catabolism | Links to GABA shunt and neurological disorders |
| ALDH7A1 | Antiquitin, involved in lysine catabolism | Model for aldehyde dehydrogenase deficiency disorders |
| ALDH4A1 | Pyrroline-5-carboxylate dehydrogenase, proline metabolism | Related to polyamine and amino acid catabolism |
| MAOB | Monoamine oxidase B, produces aldehydes from amines | Upstream of aldehyde dehydrogenase in polyamine catabolism |
| SAT1 | Spermidine/spermine N1-acetyltransferase, polyamine catabolism | Regulates substrate supply for aldehyde dehydrogenases |
| PAOX | Peroxisomal polyamine oxidase, generates 4-aminobutyraldehyde | Direct upstream enzyme for GO:0047105 substrate |
| SMOX | Spermine oxidase, produces 4-aminobutyraldehyde | Alternative source of substrate for GO:0047105 |
| GAD1 | Glutamate decarboxylase, synthesizes GABA | Alternative GABA production pathway |
| GAD2 | Glutamate decarboxylase 2, synthesizes GABA | Alternative GABA production pathway |
| ABAT | 4-aminobutyrate aminotransferase, GABA catabolism | Downstream of GABA produced by GO:0047105 |
| SSADH | Succinic semialdehyde dehydrogenase, GABA shunt | Links to TCA cycle and neurological disorders |
| NADSYN1 | NAD+ synthetase, cofactor biosynthesis | Affects NAD+ availability for GO:0047105 |
| NMNAT1 | Nicotinamide mononucleotide adenylyltransferase, NAD+ salvage | Regulates NAD+ pool for dehydrogenase activity |
How Is 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity Regulated?
The activity of 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) is regulated at multiple levels. Substrate supply is controlled by polyamine catabolic enzymes such as PAOX and SMOX, which generate 4-aminobutyraldehyde. Cofactor availability (NAD+) is determined by biosynthetic and salvage pathways, and the NAD+/NADH ratio reflects cellular metabolic state. Additionally, post-translational modifications and protein-protein interactions may modulate enzyme activity, as seen for other aldehyde dehydrogenases. Hormonal and nutritional signals that affect polyamine metabolism can indirectly influence this activity.
4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ALDH9A1 | GABA-related neurological disorders | Knockout mouse or iPSC-derived neurons |
| ALDH1A1 | Cancer stem cell maintenance | CRISPR knockout in cancer cell lines |
| ALDH2 | Alcohol sensitivity and cardiovascular disease | Point mutation knock-in mice |
| PAOX | Polyamine catabolism disorders | Overexpression and knockout cell models |
| SMOX | Neurodegeneration and cancer | Conditional knockout models |
Neurological Disorders and GABA Dysregulation
Alterations in GABA homeostasis are implicated in epilepsy, anxiety, and schizophrenia. Because GO:0047105 contributes to GABA production via the GABA shunt, its dysfunction could affect inhibitory neurotransmission. However, direct evidence linking mutations in this specific activity to disease is limited, and most insights come from studies of related aldehyde dehydrogenases.
Metabolic Disorders and Oxidative Stress
Aldehyde dehydrogenases protect against oxidative stress by detoxifying reactive aldehydes. Impaired activity can lead to aldehyde accumulation, contributing to metabolic syndrome and neurodegeneration. The NAD+-dependence also ties this activity to cellular redox balance, and NAD+ depletion is observed in aging and metabolic diseases.
Cancer and Polyamine Metabolism
Polyamine metabolism is often dysregulated in cancer, and enzymes involved in polyamine catabolism, including those upstream of GO:0047105, are potential therapeutic targets. However, the specific role of 4-trimethylammoniobutyraldehyde dehydrogenase in cancer remains to be fully elucidated.
From 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of GO:0047105 activity alter GABA levels? | CRISPR knockout of ALDH9A1 in neuronal cells |
| How does a point mutation affect catalytic efficiency? | Knock-in of specific ALDH9A1 mutations |
| Can tagging the enzyme reveal its subcellular localization? | Knock-in of fluorescent protein tag |
| Does overexpression increase GABA production? | Overexpression of ALDH9A1 in cell lines |
| What genes interact with GO:0047105? | CRISPR library screening with GABA readout |
| How does NAD+ availability regulate activity? | Knockout of NAD+ biosynthesis genes |
How to Study the 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| NADH absorbance assay | Enzyme activity via NADH production | Kinetic characterization of purified enzyme |
| LC-MS metabolomics | GABA and polyamine levels | Pathway flux analysis in cells |
| CRISPR knockout | Loss-of-function phenotypes | Gene function studies in cell lines |
| Site-directed mutagenesis | Effect of point mutations on activity | Catalytic residue identification |
| Western blot | Protein expression levels | Validation of knockout or overexpression |
| Immunofluorescence | Subcellular localization | Organelle targeting studies |
| RNA-seq | Transcriptional changes | Pathway regulation analysis |
Enzymatic Activity Assays
Direct measurement of 4-trimethylammoniobutyraldehyde dehydrogenase activity can be performed by monitoring NADH production at 340 nm using purified enzyme or cell lysates. This method is adapted from classical aldehyde dehydrogenase assays and can be used to determine kinetic parameters such as Km and Vmax.
Genetic Knockout and Knock-in Models
CRISPR-Cas9 technology enables the generation of knockout cell lines and animal models to study loss-of-function phenotypes. Point mutations can be introduced to dissect catalytic residues, while knock-in of tags allows visualization and affinity purification. These approaches are essential for linking genotype to metabolic outcomes.
Metabolomics and Flux Analysis
Mass spectrometry-based metabolomics can quantify GABA and polyamine intermediates, providing a readout of pathway flux. Isotope tracing can reveal how substrates flow through the GABA shunt and identify compensatory pathways.
Transcriptomics and Proteomics
RNA-seq and proteomics can assess expression changes in genes related to GO:0047105 under different conditions. Co-expression analysis may identify regulatory networks and potential interacting partners.
How CRISPR Can Be Used to Study GO:0047105 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity
Knockout
CRISPR knockout of genes encoding GO:0047105 activity, such as ALDH9A1, can abolish GABA production via this route. This is useful for determining the contribution of this enzyme to total GABA levels and for identifying compensatory pathways. Knockout models can also reveal developmental or metabolic phenotypes.
Point Mutation
Introducing point mutations in catalytic residues (e.g., the active-site cysteine) can dissect the mechanism of hydride transfer and substrate specificity. Such models are valuable for understanding how subtle genetic variations affect enzyme function and may mimic human polymorphisms.
Knock-in
Knock-in of epitope tags or fluorescent proteins allows real-time tracking of enzyme localization and dynamics. This approach can also be used to introduce disease-associated mutations or to create reporter lines for high-throughput screening.
Overexpression
Overexpression of the enzyme can increase flux through the GABA shunt, potentially elevating GABA levels. This is useful for metabolic engineering and for studying the consequences of enhanced activity in cellular models.
How EDITGENE Supports 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity Research
Researchers studying 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity-related genes often need to determine whether a candidate gene is causally involved in metabolic or neurological phenotypes. EDITGENE provides a comprehensive suite of CRISPR services to accelerate this research, from gene knockout to precise point mutations and library screening.
Contact EDITGENE today to design your custom CRISPR model for 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity research.
Frequently Asked Questions About 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity
What is 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity?
It is an enzyme activity defined by GO:0047105 that catalyzes the NAD+-dependent oxidation of 4-(trimethylamino)butanal to 4-(trimethylamino)butanoate (GABA).
What genes are involved in 4-trimethylammoniobutyraldehyde dehydrogenase (NAD+) activity?
Genes such as ALDH9A1 encode enzymes with this activity, and upstream genes like PAOX and SMOX supply the substrate.
What is the reaction catalyzed by GO:0047105?
The reaction is: 4-(trimethylamino)butanal + NAD+ + H2O = 4-(trimethylamino)butanoate + NADH + 2 H+.
How is this enzyme regulated?
It is regulated by substrate availability, NAD+ levels, and possibly post-translational modifications, as seen for related aldehyde dehydrogenases.
What diseases are associated with this activity?
Dysregulation may contribute to neurological disorders and metabolic stress, though direct evidence is limited.
What methods are used to study this activity?
Enzymatic assays, metabolomics, CRISPR knockout, and proteomics are commonly used.
Can CRISPR be used to study GO:0047105?
Yes, CRISPR knockout, point mutation, and knock-in models can precisely manipulate genes encoding this activity.
What is the role of NAD+ in this reaction?
NAD+ acts as an electron acceptor, being reduced to NADH, which must be regenerated for sustained activity.
Is this enzyme found in humans?
Yes, human aldehyde dehydrogenases such as ALDH9A1 exhibit this activity.
What is the GABA shunt?
The GABA shunt is a metabolic pathway that bypasses two TCA cycle steps to produce succinate from GABA, and GO:0047105 contributes to GABA synthesis.
Conclusion
GO:0047105 represents a specific NAD+-dependent aldehyde dehydrogenase activity that bridges polyamine catabolism and GABA production. While direct disease links are still emerging, its role in neurotransmitter homeostasis and cellular redox balance makes it a compelling target for metabolic and neurological research. Leveraging CRISPR-based models and advanced analytical methods will further elucidate its physiological significance.
References
- 1. Holloszy JO. 1967. Biochemical adaptations in muscle. Effects of exercise on mitochondrial oxygen uptake and respiratory enzyme activity in skeletal muscle.. J Biol Chem 242(9):2278-82 PMID: 4290225
- 2. Taxon ES et al.. 2020. Kinetics aspects of Gamma-hydroxybutyrate dehydrogenase.. Biochim Biophys Acta Proteins Proteom 1868(5):140376 PMID: 31981617
- 4. Tago K et al.. 1982. 4-Aminobutyraldehyde dehydrogenase activity in rat brain.. J Neurochem 39(3):803-9 PMID: 7097287
- 5. Furukawa S et al.. 1981. Inhibition of lactate dehydrogenase activity by polymeric NAD derivatives with different NAD densities.. Eur J Biochem 114(1):101-4 PMID: 7011800
- 8. Sidhu RS et al.. 1975. Human liver aldehyde dehydrogenase. Esterase activity.. J Biol Chem 250(19):7894-8 PMID: 170275
